Inspira Technologies has announced a strategic partnership with Westchester Medical Center to assess the effectiveness and performance of its INSPIRA ART100 systems.
This partnership aims to expose Inspira's technologies to medical professionals and institutions, potentially focusing on patient care in respiratory failure scenarios.
Through this collaboration, Westchester Medical Center and Inspira will deploy the INSPIRA ART100 systems for advancing critical patient care.
The aim is to explore long-term cooperation for the future deployment of Inspira's INSPIRA ART technology, which is being designed to address acute respiratory failure by rapidly improving oxygen saturation levels without the need for mechanical ventilation.
Inspira Technologies co-founder and president Joe Hayon said: "We are thrilled to supply Westchester Medical Center with our FDA-cleared INSPIRA ART100 systems.
"We believe that this collaboration validates the growing interest in our innovative technology and also provides us with an opportunity to demonstrate its capabilities in one of New York's premier medical networks."
INSPIRA ART features the HYLA blood sensor, a new technology that provides continuous real-time blood monitoring.
This sensor is designed to alert physicians to changes in a patient's condition, potentially enabling more informed decision-making without the need for frequent blood samples.
Inspira Technologies has already achieved the Food and Drug Administration (FDA) 510(k) clearance for its INSPIRA ART100 system for use during cardiopulmonary bypass procedures.
Additionally, the system has received certification from the Israeli AMAR for extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures.
While the INSPIRA ART100 system has been cleared, the company’s other products, including the INSPIRA ART500 or Gen 2, the INSPIRA Cardi-ART portable modular device, the VORTX orbiting oxygen delivery system, and the HYLA blood sensor, are still under development. These products have not yet been tested in humans and await approval from regulatory entities.
